Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 2Carcinoma, Renal Cell 2Neoplasms 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 26Nivolumab 18enfortumab vedotin 7avelumab 6atezolizumab 6Ipilimumab 6Magnetic Resonance Spectroscopy 5fludarabine 4cabozantinib 4Gemcitabine 4Cyclophosphamide 4Carboplatin 4Specimen Handling 3Interleukin-2 3Docetaxel 3130-nm albumin-bound paclitaxel 3aldesleukin 2Platinum 2Pemetrexed 2Paclitaxel 2Oxaliplatin 2Immunoglobulin G 2Fluorodeoxyglucose F18 2FAPI-46 2Disulfides 2Cisplatin 2Albumin-Bound Paclitaxel 2vinflunine 1veliparib 1valrubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Transitional Cell × sotigalimab × Clear all
NCT02482168 2023-12-20

Study of the CD40 Agonistic Monoclonal Antibody APX005M

Apexigen America, Inc.

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryHead & Neck

Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡